These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26061388)

  • 1. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
    Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
    J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
    Fauber BP; Gobbi A; Robarge K; Zhou A; Barnard A; Cao J; Deng Y; Eidenschenk C; Everett C; Ganguli A; Hawkins J; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Ouyang W; Tang W; Wong H
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2907-12. PubMed ID: 26048793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reversed sulfonamide series of selective RORc inverse agonists.
    van Niel MB; Fauber BP; Cartwright M; Gaines S; Killen JC; René O; Ward SI; de Leon Boenig G; Deng Y; Eidenschenk C; Everett C; Gancia E; Ganguli A; Gobbi A; Hawkins J; Johnson AR; Kiefer JR; La H; Lockey P; Norman M; Ouyang W; Qin A; Wakes N; Waszkowycz B; Wong H
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5769-5776. PubMed ID: 25453817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.
    Fauber BP; Gobbi A; Savy P; Burton B; Deng Y; Everett C; La H; Johnson AR; Lockey P; Norman M; Wong H
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4109-13. PubMed ID: 26321361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tertiary sulfonamides as RORc inverse agonists.
    Fauber BP; René O; Burton B; Everett C; Gobbi A; Hawkins J; Johnson AR; Liimatta M; Lockey P; Norman M; Wong H
    Bioorg Med Chem Lett; 2014 May; 24(9):2182-7. PubMed ID: 24685544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.
    Fauber BP; René O; de Leon Boenig G; Burton B; Deng Y; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; La H; Liimatta M; Lockey P; Norman M; Ouyang W; Wang W; Wong H
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3891-7. PubMed ID: 25017032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
    Fauber BP; Magnuson S
    J Med Chem; 2014 Jul; 57(14):5871-92. PubMed ID: 24502334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
    Fauber BP; de Leon Boenig G; Burton B; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; Liimatta M; Lockey P; Norman M; Ouyang W; René O; Wong H
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6604-9. PubMed ID: 24239186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.
    Wu XS; Wang R; Xing YL; Xue XQ; Zhang Y; Lu YZ; Song Y; Luo XY; Wu C; Zhou YL; Jiang JQ; Xu Y
    Acta Pharmacol Sin; 2016 Nov; 37(11):1516-1524. PubMed ID: 27374490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.
    Ouvry G; Atrux-Tallau N; Bihl F; Bondu A; Bouix-Peter C; Carlavan I; Christin O; Cuadrado MJ; Defoin-Platel C; Deret S; Duvert D; Feret C; Forissier M; Fournier JF; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Huguet H; Lafitte G; Luzy AP; Musicki B; Orfila D; Ozello B; Pascau C; Pascau J; Parnet V; Peluchon G; Pierre R; Piwnica D; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
    ChemMedChem; 2018 Feb; 13(4):321-337. PubMed ID: 29327456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties.
    René O; Fauber BP; Barnard A; Chapman K; Deng Y; Eidenschenk C; Everett C; Gobbi A; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Wong H
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4455-4461. PubMed ID: 27524313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α.
    Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM
    Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.
    Olsson RI; Xue Y; von Berg S; Aagaard A; McPheat J; Hansson EL; Bernström J; Hansson P; Jirholt J; Grindebacke H; Leffler A; Chen R; Xiong Y; Ge H; Hansson TG; Narjes F
    ChemMedChem; 2016 Jan; 11(2):207-16. PubMed ID: 26553345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.
    Song Y; Xue X; Wu X; Wang R; Xing Y; Yan W; Zhou Y; Qian CN; Zhang Y; Xu Y
    Eur J Med Chem; 2016 Jun; 116():13-26. PubMed ID: 27043267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.
    Wang Y; Liu H
    J Med Chem; 2018 Dec; 61(23):10412-10414. PubMed ID: 30507131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.
    Schnute ME; Wennerstål M; Alley J; Bengtsson M; Blinn JR; Bolten CW; Braden T; Bonn T; Carlsson B; Caspers N; Chen M; Choi C; Collis LP; Crouse K; Färnegårdh M; Fennell KF; Fish S; Flick AC; Goos-Nilsson A; Gullberg H; Harris PK; Heasley SE; Hegen M; Hromockyj AE; Hu X; Husman B; Janosik T; Jones P; Kaila N; Kallin E; Kauppi B; Kiefer JR; Knafels J; Koehler K; Kruger L; Kurumbail RG; Kyne RE; Li W; Löfstedt J; Long SA; Menard CA; Mente S; Messing D; Meyers MJ; Napierata L; Nöteberg D; Nuhant P; Pelc MJ; Prinsen MJ; Rhönnstad P; Backström-Rydin E; Sandberg J; Sandström M; Shah F; Sjöberg M; Sundell A; Taylor AP; Thorarensen A; Trujillo JI; Trzupek JD; Unwalla R; Vajdos FF; Weinberg RA; Wood DC; Xing L; Zamaratski E; Zapf CW; Zhao Y; Wilhelmsson A; Berstein G
    J Med Chem; 2018 Dec; 61(23):10415-10439. PubMed ID: 30130103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
    Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
    Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
    Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.